The primary antibody deficient patients, of whom the majority had CVID or XLA, had lower baseline levels of serum IgM and IgA and fewer switched memory B cells than the secondary patients before Ig-replacement therapy. This evidence concerns the gene CD79A and common variable immunodeficiency.